Is this the last word on secretin?

From Volume 3 Number 6, 2003

SEATTLE, Washington, USA: Secretin, touted as a possible cure for autism just three years ago, is not a magic bullet that relieves the symptoms of the developmental disorder, researchers at the University of Washington and the University of Colorado Health Sciences Center report.

            Their study, which involved the largest and most comprehensive trials of the hormone yet conducted, is published in the November 2002 issue of the Journal of the American Academy of Child Adolescent Psychiatry.

            “The message to parents is that there is no evidence that secretin is effective and should be given to children with autism,” said Dr Geraldine Dawson, director of the University of Washington’s Autism Center, who co-led the study. “We have yet to find a medicine that cures autism, and the results really underscore why research into the cause of autism is necessary.”

            The study is believed to be the first to measure the effectiveness of both natural porcine secretin and a synthetic form of the hormone and a placebo. Secretin is a naturally occurring human hormone produced in the small intestine that helps control digestion and is used in diagnosing gastrointestinal problems.

            Autism is a disorder which interferes with a child’s ability to communicate and relate socially with other people. Affected individuals can also have a restricted range of activities and interests, and about 75 per cent of children with autism also have some form of mental retardation. The disorder is far more common than previously thought, affecting more than half a million Americans.

            The researchers found that neither form of secretin reduced the symptoms of autism beyond the effects noted for the placebo.

            “With autism, we know there is a very large placebo effect, so you have to show a bigger effect to say a treatment worked,” said Dr Dawson. “We don’t fully understand the mystery of the placebo effect in medicine. But the expectancy that a treatment will work can have a real positive impact. It is not an imagined effect, but real change because of the expectancy of some possible change.”

            Dr Dawson told Adam Feinstein, Editor of Looking Up:  “The placebo effect can be really startling, at times.”

            In the study, 85 children diagnosed with autism and ranging in age from three to 12 years were each given a single intravenous injection of one type of secretin or a placebo in randomised, double-blind trials.

            The children were evaluated on a number of factors, including language, social functioning and behavioural problems by parents, teachers and researchers one week before receiving the injection and again four weeks after being injected. None of those doing the evaluations knew what type of injection each child received. Parents were asked about their child’s behavioural and sleep problems and their vocabulary, while teachers were primarily asked about behavioural problems. In laboratories, investigators rated and diagnosed the children in a play-based interaction that tested social and communication functioning. The children were also given a vocabulary test.

            In addition, the researchers compared children with and without gastrointestinal problems, common symptoms for many people with autism. The initial report claiming benefits from secretin in the late 1990s came from a study in which the hormone was used in diagnosing a child’s gastrointestinal problems. Again, Dr Dawson said, the new study showed that there was no response beyond that shown from the placebo.

            “Secretin is not a magic bullet,” she said. “When parents first heard about the initial reports, some were paying huge sums of money for secretin treatment. The National Institutes of Health decided to commission this study  in response to a high-visibility case where parents were using a treatment that had not been assessed. The available evidence suggests there is no role for secretin. There is still a possibility that repeated doses of secretin might have an effect. But we think parents should use treatments that we know are effective, such as behavioural interventions and, in some cases, drugs to treat associated symptoms such as attention problems and hyperactivity which affect many children with autism.”

Looking Up, 16-page English PDF Edition, Back Issues and Current Issue

Looking Up, Volume 5 Number 1 PDF edition front cover Looking Up, Volume 5 Number 2 PDF edition front cover Looking Up, Volume 5 Number 3 PDF edition front cover Looking Up, Volume 5 Number 4 PDF edition front cover
Looking Up, Volume 5 Number 5 PDF edition front cover Looking Up, Volume 5 Number 6 PDF edition front cover Looking Up, Volume 5 Number 7 PDF edition front cover Looking Up, Volume 5 Number 8 PDF edition front cover

Current 40-page print edition issue
Current print edition of Looking Up


Email (general enquiries)
Email (subscription/order enquiries):
Postal address:Looking Up, PO Box 25727, London, SW19 1WF, UK
Telephone (London, UK):+44-208-5427702, or 0208-5427702 from the UK
FAX (UK):+44-871-3140327, or 0871-3140327 from the UK
Our Home Page:

Search our autism pages

VOLUME 1, Number: 1 2 3 4 5 6 7 8 9 10 11 12   VOLUME 2, Number: 1 2 3 4 5 6 7 8 9 10 11 12
VOLUME 3, Number: 1 2 3 4 5 6 7 8 9 10 11 12   VOLUME 4, Number: 1 2 3 4 5 6 7 8 9 10 11 12
VOLUME 5, Number: 1 2 3 4 5 6 7 8


We use third-party advertising companies to serve ads when you visit our website. These companies may use information (not including your name, address, email address or telephone number) about your visits to this and other websites in order to provide advertisements about goods and services of interest to you. If you would like more information about this practice and would like to know your options in relation to·not having this information used by these companies, click here.

Copyright declaration

Materials available from these web pages are copyright © unless otherwise stated.